Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
To determine the effect of ixazomib maintenance therapy on progression-free survival (PFS), defined as the time from randomization to progressive disease (PD) or death from any cause, compared with placebo, in patients with NDMM who have had a major response - defined as complete response (CR), very good partial response (VGPR), or partial response (PR) - to initial therapy and who have not undergone SCT
Inclusion criteria
- Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation